JP2008303182A - 等張液 - Google Patents
等張液 Download PDFInfo
- Publication number
- JP2008303182A JP2008303182A JP2007152498A JP2007152498A JP2008303182A JP 2008303182 A JP2008303182 A JP 2008303182A JP 2007152498 A JP2007152498 A JP 2007152498A JP 2007152498 A JP2007152498 A JP 2007152498A JP 2008303182 A JP2008303182 A JP 2008303182A
- Authority
- JP
- Japan
- Prior art keywords
- water
- seawater
- salt
- deep
- sea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000644 isotonic solution Substances 0.000 title claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 115
- 239000013535 sea water Substances 0.000 claims abstract description 92
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 71
- 239000013505 freshwater Substances 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- 230000003204 osmotic effect Effects 0.000 claims abstract description 25
- 238000010790 dilution Methods 0.000 claims abstract description 18
- 239000012895 dilution Substances 0.000 claims abstract description 18
- 239000002504 physiological saline solution Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 28
- 239000011780 sodium chloride Substances 0.000 abstract description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 18
- 235000010755 mineral Nutrition 0.000 abstract description 18
- 239000011707 mineral Substances 0.000 abstract description 18
- 239000012153 distilled water Substances 0.000 abstract description 7
- 239000000243 solution Substances 0.000 abstract description 3
- 210000004381 amniotic fluid Anatomy 0.000 abstract description 2
- 210000003754 fetus Anatomy 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000012266 salt solution Substances 0.000 abstract 3
- 210000004185 liver Anatomy 0.000 description 25
- 238000000909 electrodialysis Methods 0.000 description 19
- 238000010186 staining Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 11
- 238000001000 micrograph Methods 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000001223 reverse osmosis Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000030968 tissue homeostasis Effects 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000003749 cleanliness Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003014 ion exchange membrane Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000001557 animal structure Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000010001 cellular homeostasis Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- JWUKKEHXERVSKS-UHFFFAOYSA-M silver;periodate Chemical compound [Ag+].[O-]I(=O)(=O)=O JWUKKEHXERVSKS-UHFFFAOYSA-M 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 101000835317 Mus musculus Thioredoxin Proteins 0.000 description 1
- 101000801890 Mus musculus Thioredoxin, mitochondrial Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007152498A JP2008303182A (ja) | 2007-06-08 | 2007-06-08 | 等張液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007152498A JP2008303182A (ja) | 2007-06-08 | 2007-06-08 | 等張液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008303182A true JP2008303182A (ja) | 2008-12-18 |
| JP2008303182A5 JP2008303182A5 (enrdf_load_stackoverflow) | 2010-04-30 |
Family
ID=40232206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007152498A Pending JP2008303182A (ja) | 2007-06-08 | 2007-06-08 | 等張液 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2008303182A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010037275A (ja) * | 2008-08-05 | 2010-02-18 | Goshu Yakuhin Kk | 海洋深層水を原料とする外用剤 |
| WO2019244836A1 (ja) * | 2018-06-18 | 2019-12-26 | 五洲薬品株式会社 | 細胞培養用溶液の製造方法、細胞培養用溶液、液体培地、細胞培養用処理液、および細胞増殖活性増強剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002292371A (ja) * | 2001-01-23 | 2002-10-08 | Goshu Yakuhin Kk | 海洋深層水より分離した淡水と濃縮深層水とミネラル濃縮液と濃縮塩水と苦汁と特殊塩 |
| JP2002326941A (ja) * | 2001-05-01 | 2002-11-15 | Naomasa Morita | 眼科用剤 |
| JP2005281238A (ja) * | 2004-03-30 | 2005-10-13 | Yoriyoshi Kumagai | 海水を利用した医療用電解質液およびその製造方法 |
-
2007
- 2007-06-08 JP JP2007152498A patent/JP2008303182A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002292371A (ja) * | 2001-01-23 | 2002-10-08 | Goshu Yakuhin Kk | 海洋深層水より分離した淡水と濃縮深層水とミネラル濃縮液と濃縮塩水と苦汁と特殊塩 |
| JP2002326941A (ja) * | 2001-05-01 | 2002-11-15 | Naomasa Morita | 眼科用剤 |
| JP2005281238A (ja) * | 2004-03-30 | 2005-10-13 | Yoriyoshi Kumagai | 海水を利用した医療用電解質液およびその製造方法 |
Non-Patent Citations (3)
| Title |
|---|
| JPN6012050181; 八田秀樹， ｅｔ ａｌ．: '海洋深層水成分の病理組織診断への応用' 医学と薬学 Ｖｏｌ． ５７， Ｎｏ． ５, 20070525, ｐ． ６１５-６２０ * |
| JPN6012050185; '深層水移植用臓器保存液に' 読売新聞 富山１３版, 20070116, ｐ． ３１ * |
| JPN6012050189; 牧田登之: '沖縄深層水に浸漬した豚の肝臓、脾臓、腎臓の組織変化について' 熱帯海域及び生体物における深層水利用の調査研究-日本財団助成事業平成１３年度研究成果報告書- , 2002, ｐ． １３７-１４８ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010037275A (ja) * | 2008-08-05 | 2010-02-18 | Goshu Yakuhin Kk | 海洋深層水を原料とする外用剤 |
| WO2019244836A1 (ja) * | 2018-06-18 | 2019-12-26 | 五洲薬品株式会社 | 細胞培養用溶液の製造方法、細胞培養用溶液、液体培地、細胞培養用処理液、および細胞増殖活性増強剤 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Webb | Ionic regulation in Carcinus maenas | |
| Elloumi et al. | Composition and distribution of planktonic ciliates from ponds of different salinity in the solar saltwork of Sfax, Tunisia | |
| JP2008063258A (ja) | 組織保存液 | |
| Dellasega et al. | Regulation of renal tubule cell volume in hypotonic media | |
| Gordon et al. | Osmotic regulation in the tadpoles of the crab-eating frog (Rana cancrivora) | |
| Freire et al. | Special challenges to teleost fish osmoregulation in environmentally extreme or unstable habitats | |
| JPH07507266A (ja) | アルデヒド安定化溶液を用いる方法および組成物 | |
| Cowan | The ultrastructure of the lachrymal'salt'gland and the Harderain gland in the euryhaline Malaclemys and some closely related stenohaline emydines | |
| Abdo et al. | Pulmonary zygomycosis with Cunninghamella bertholletiae in a killer whale (Orcinus orca) | |
| CN111793604B (zh) | 一种耐奥希替尼的人非小细胞肺癌细胞株h1975/or及其应用 | |
| CN108106909B (zh) | 一种生物组织光透明剂、光透明化方法及其应用 | |
| JP2008303182A (ja) | 等張液 | |
| Gómez-Acata et al. | Methods for extracting'omes from microbialites | |
| Hong et al. | Effect of salinity on the survival, ions and urea modulation in red-eared slider (Trachemys scripta elegans) | |
| van den Hoff et al. | The ciliate Mesodinium rubrum and its cryptophyte prey in Antarctic aquatic environments | |
| Golubkov et al. | Biodiversity and the functioning of hypersaline lake ecosystems from Crimea Peninsula (Black Sea) | |
| Mancini et al. | Main diseases of pejerrey (Odontesthes bonariensis) in central Argentina | |
| Panagiotis et al. | Brain and liver histopathological examination of Carassius gibelio from a newly reconstructed lake with toxic cyanobacteria | |
| Jarial et al. | Ultrastructural study of the kidney in the coelacanth Latimeria chalumnae (Rhipidistia: Coelacanthini) | |
| Buanes et al. | Histochemical localization of carbonic anhydrase in the pig's exocrine pancreas | |
| Sönmez et al. | Variations in Afrolaophonte pori Masry, 1970 (Copepoda: Harpacticoida: Laophontidae): a contribution towards the revision of the genus | |
| Dunson | The contrasting roles of the salt glands, the integument and behavior in osmoregulation of marine reptiles | |
| Fritz et al. | Radial transport of salt and water in roots of the common reed (P hragmites australis T rin. ex S teudel) | |
| Keller et al. | Nephrolithiasis and pyelonephritis in two West Indian manatees (Trichechus manatus spp.) | |
| Grigg et al. | 11 Salt and Water Balance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20070612 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100316 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100526 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100526 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110601 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130219 |